NCT03275493 2024-05-28
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
Clinical Trials
24 trialsNCT04601584 2024-03-06
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
AO GENERIUM
Phase 1/2 Unknown
NCT06087419 2023-11-02
A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Unknown
NCT05429905 2023-03-09
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
KK Women's and Children's Hospital
Phase 1/2 Unknown
NCT03467256 2023-02-24
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 1/2 Unknown
NCT05587088 2022-10-19
PA001
Hospital Universitario San Ignacio
Phase 1/2 Unknown
NCT04764513 2022-03-28
Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT05066958 2021-10-04
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 1/2 Unknown
NCT02772198 2020-11-03
T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies
Sheba Medical Center
Phase 1/2 Unknown
NCT04206943 2020-01-27
ISIKOK-19
Acibadem University
Phase 1/2 Unknown
NCT02965092 2019-05-10
CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
Phase 1/2 Unknown
NCT03366350 2019-05-10
Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
Phase 1/2 Unknown
NCT02310243 2019-04-16
Study of Palbociclib in MLL-rearranged Acute Leukemias
University of Ulm
Phase 1/2 Unknown
NCT03366324 2018-11-20
Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
Phase 1/2 Unknown
NCT03544021 2018-06-04
CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 1/2 Unknown
NCT03091933 2017-12-06
GLIDE
Ciusss de L'Est de l'Île de Montréal
Phase 1/2 Unknown
NCT03191773 2017-06-20
A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2 Unknown
NCT02892695 2016-12-06
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1/2 Unknown
NCT02819583 2016-10-25
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1/2 Unknown
NCT02851589 2016-08-01
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1/2 Unknown
NCT01354457 2014-06-25
RIT 90YEpra
Nantes University Hospital
Phase 1/2 Unknown
NCT02007811 2014-03-26
B-cell therapy
University of Erlangen-Nürnberg Medical School
Phase 1/2 Unknown
NCT01037556 2012-08-31
PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia
Proacta, Incorporated
Phase 1/2 Unknown
NCT00271063 2007-12-21
Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia
Callisto Pharmaceuticals
Phase 1/2 Unknown